Thromb Haemost 1991; 65(01): 102-106
DOI: 10.1055/s-0038-1647462
Original Article
Schattauer GmbH Stuttgart

Platelet Agglutinating Protein p37 Causes Platelet Agglutination through its Binding to Membrane Glycoprotein IV

Eric C-Y Lian
1   The Medical and Research Services, Veterans Administration Medical Center, and the Hemophilia and Thrombosis Center, W. J. Harrington Center for Blood Diseases, University of Miami, School of Medicine, Miami, Florida, USA
,
Farooq A Siddiqui
1   The Medical and Research Services, Veterans Administration Medical Center, and the Hemophilia and Thrombosis Center, W. J. Harrington Center for Blood Diseases, University of Miami, School of Medicine, Miami, Florida, USA
,
G A Jamieson
2   The Laboratory of Cell Biology, American Red Cross, Rockville, Maryland, USA
,
Narendra N Tandon
2   The Laboratory of Cell Biology, American Red Cross, Rockville, Maryland, USA
› Author Affiliations
Further Information

Publication History

Received 20 April 1990

Accepted after revision 12 August 1990

Publication Date:
02 July 2018 (online)

Summary

A 37 kDa platelet agglutinating protein (PAP p37) has previously been shown to be present in a subset of patients with thrombotic thrombocytopenic purpura and has been purified from their plasma. Using solubilized platelet membrane proteins from normal donors, it was shown by Western blotting that r2sI-p37 bound to a membrane protein of 97 kDa (red/unred). Furthernore, the same protein was identified by reverse immunoblotting in which purified p37 was electrophoresed, transferred to the nitrocellulose sheet and incubated with solubilized normal platelet membrane proteins. The complex formed between p37 and the membrane protein was identified by autoradiography using polyclonal and monoclonal (OKM5) anti- GPIV antibodies, but was not detected by polyclonal antibody to GPIIIa. Similar studies with purified platelet GPIV under both reducing and non-reducing conditions demonstrated the binding of 125I-p37. Polyclonal and monoclonal antibodies to GPIV completely inhibited the platelet agglutination induced by TTP plasma containing p37, however, normal rabbit IgG, rabbit anti- GPIIIa IgG, and murine monoclonal anti-GPIIb/IIIa (10E5) antibodies had no effect. These data indicate that platelet GPIV is the receptor site for PAP p37.

 
  • References

  • 1 Lian EC Y, Harkness DR, Byrness JJ, Wallach H, Nuñez R. The presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura and its inhibition by normal plasma. Blood 1979; 53: 333-338
  • 2 Ansell J, Slepchuk NI, Pechet L. Thrombotic thrombocytopenic purpura. Blood 1979; 54: 959-960
  • 3 Brandt JT, Kennedy MS, Senhauser DA. Platelet aggregating factor in thrombotic thrombocytopenic purpura. Lancet 1979; 2: 463-464
  • 4 Siddiqui FA, Lian EC Y. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma. J Clin Invest 1985; 76: 1330-1337
  • 5 Lian EC Y, Siddiqui FA. Binding of platelet agglutinating protein p37 from the plasma of a patient with thrombotic thrombocytopenic purpura to human platelets. Blood (Suppl. 01) 1987; 70: 341a
  • 6 Lian EC Y, Siddiqui FA. Investigation of the role of von Willebrand factor in thrombotic thrombocytopenic purpura. Blood 1985; 66: 1219-1221
  • 7 Lian EC Y, Siddiqui FA. Von Willebrand factor in TTP. Blood 1986; 67: 1524-1526
  • 8 Siddiqui FA, Lian EC Y. Platelet-agglutinating protein p37 from a thrombotic thrombocytopenic purpura plasma forms a complex with human immunoglobulin-G. Blood 1988; 71: 299-304
  • 9 Tandon NN, Lipsky RH, Burgess WH, Jamieson GA. Isolation and characterization of platelet glycoprotein IV (CD36). J Biol Chem 1989; 264: 7570-7575
  • 10 Fitzgerald LA, Leung B, Phillips DR. A Method for purifying the platelet membrane glycoprotein IIb-IIIa complex. Anal Biochem 1985; 151: 169-177
  • 11 Phillips DR, Agin PP. Platelet plasma membrane glycoproteins. J Biol Chem 1977; 252: 2121-2126
  • 12 Beer J, Coller BS. Evidence that platelet glycoprotein IIIa has a large disulfide-bonded loop that is susceptible to proteolytic cleavage. J Biol Chem 1989; 264: 17564-17573
  • 13 Walsh PN, Mills DCB, White JG. Metabolism and function of human platelets washed by albumin density gradient separation. Br J Haematol 1977; 36: 287-296
  • 14 Asch A, Barnwell J, Silverstein RL, Nachman RL. Isolation of the thrombospondin membrane receptor. J Clin Invest 1987; 79: 1054-1061
  • 15 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680-685
  • 16 Kwaan HC. The pathogenesis of thrombotic thrombocytopenic purpura. Semin Thromb Hemostas 1979; 3: 184-198
  • 17 Lian EC Y. Pathogenesis of thrombotic thrombocytopenic purpura. Semin Hematology 1987; 24: 82-100
  • 18 Tandon NN, Hines A, Jamieson GA. Role for glycoprotein IV in collagen induced platelet aggregation. Blood (Suppl. 01) 1985; 66: 316a
  • 19 Tusji T, Osawa T. Purification and chemical characterization of human platelet membrane glycoprotein IV. J Biochem 1986; 100: 1077-1085
  • 20 Tandon NN, Kralisz U, Jamieson GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 1989; 264: 7576-7583
  • 21 Ockenhouse CF, Tandon NN, Magowan C, Jamieson GA, Chulay JD. Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science 1989; 243: 1469-1471
  • 22 Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest 1989; 84: 546-552
  • 23 Bolin RB, Okumura T, Jamieson GA. Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders. Am J Hematol 1977; 3: 63-71